After more than a decade of debate, research, surveys, and global collaboration, one of the world’s most recognized women’s health conditions has officially received a new name. Polycystic ovary syndrome, long known as PCOS, will now be called polyendocrine metabolic ovarian syndrome, or PMOS. The change was announced this week at the European Congress of Endocrinology in Prague and published in The Lancet. Behind the update was a 14-year international effort led by Professor Helena Teede, Director of the Monash Centre for Health Research & Implementation and endocrinologist at Monash Health.
For many clinicians, the move may feel overdue. The term “polycystic ovary syndrome” has long frustrated researchers and patients alike because the condition is not actually defined by ovarian cysts. Experts involved in the renaming effort argued that the old terminology narrowed clinical focus to…
